doi: 10.1016/S0140-6736(19)32517-6 Summary Keywords non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, obesity, insulin resistance, metabolic syndrome, metabolic disease, fibroblast growth factor 21 Citation Tillman EJ and Rolph T (2020) FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Safety Profile: What You Actually Need to Know No drug class with this breadth of benefit is without side effects, and intellectual honesty requires addressing them directly
Hydration is Critical GLP-1 medications can sometimes mask thirst or lead to dehydration if you experience nausea
Tirzepatide is a newer medication that takes weight loss treatment a step further
Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D(3)-fortified bread and milk during winter in Denmark
We already know how GLP-1s impact body weight and insulin resistance, diabetes and gut health, Ezici told Healio
